Literature DB >> 19563924

Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women.

M F Sowers1, C A Karvonen-Gutierrez, M Yosef, M Jannausch, Y Jiang, P Garnero, J Jacobson.   

Abstract

OBJECTIVE: To ascertain the predictive role of longitudinally acquired biochemical measures of cartilage turnover in relation to X-ray defined knee osteoarthritis (OAK), knee pain and functioning.
METHODS: This is a feasibility study based on 72 enrollees of the Michigan site of Study of Women's Health Across the Nation (SWAN), a longitudinal, population-based cohort study with 11 annual visits to characterize health at the mid-life. At visits in 1996, 1998 and 2007, radiographs were evaluated for the presence of OAK [>or=2 on the Kellgren and Lawrence (K-L) scale]. Knee pain and stiffness were assessed by interview. Functioning was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Cartilage oligomeric matrix protein (COMP) and Type II collagen telopeptides (CTX-II) were assayed in serum and urine samples collected on alternate years from 1997 to 2006. We related trajectories of the cartilage biochemical markers from these five time points to OAK severity (no OAK, K-L score<2; mild OAK, K-L score=2; moderate/severe OAK, K-L score=3 or 4), pain, stiffness, or functioning, using longitudinal non-linear mixed modeling.
RESULTS: The 2007 prevalence of X-ray defined OAK was 50% in these 72 women. Upward trajectories of COMP (P=0.02) and CTX-II (P=0.006) were associated with increased OAK severity and body size. COMP trajectories were associated with pain and stiffness, but not functioning. CTX-II trajectories were associated with stiffness scores, but not knee pain or functioning scores.
CONCLUSION: Multiple, biennial measures of COMP or CTX-II taken over a 10-year period were predictive of subsequent OAK and knee stiffness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563924      PMCID: PMC2788064          DOI: 10.1016/j.joca.2009.06.001

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  34 in total

1.  Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.

Authors:  P Garnero; M Piperno; E Gineyts; S Christgau; P D Delmas; E Vignon
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Collagen type II C-telopeptide fragments as an index of cartilage degradation.

Authors:  S Christgau; P Garnero; C Fledelius; C Moniz; M Ensig; E Gineyts; C Rosenquist; P Qvist
Journal:  Bone       Date:  2001-09       Impact factor: 4.398

3.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.

Authors:  Patrick Garnero; Xavier Ayral; Jean-Charles Rousseau; S Christgau; Linda J Sandell; Maxime Dougados; Pierre D Delmas
Journal:  Arthritis Rheum       Date:  2002-10

4.  COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage.

Authors:  G Müller; A Michel; E Altenburg
Journal:  Connect Tissue Res       Date:  1998       Impact factor: 3.417

5.  Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.

Authors:  P Garnero; W S Aronstein; S B Cohen; P G Conaghan; G A Cline; C Christiansen; J F Beary; J M Meyer; C O Bingham
Journal:  Osteoarthritis Cartilage       Date:  2007-11-13       Impact factor: 6.576

6.  A new marker for osteoarthritis: cross-sectional and longitudinal approach.

Authors:  M Reijman; J M W Hazes; S M A Bierma-Zeinstra; B W Koes; S Christgau; C Christiansen; A G Uitterlinden; H A P Pols
Journal:  Arthritis Rheum       Date:  2004-08

7.  Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis.

Authors:  V Vilím; M Olejárová; S Machácek; J Gatterová; V B Kraus; K Pavelka
Journal:  Osteoarthritis Cartilage       Date:  2002-09       Impact factor: 6.576

8.  Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI.

Authors:  E B Dam; I Byrjalsen; M A Karsdal; P Qvist; C Christiansen
Journal:  Osteoarthritis Cartilage       Date:  2008-09-03       Impact factor: 6.576

9.  Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis.

Authors:  M Jung; S Christgau; M Lukoschek; D Henriksen; W Richter
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

10.  Magnetic resonance-detected subchondral bone marrow and cartilage defect characteristics associated with pain and X-ray-defined knee osteoarthritis.

Authors:  M F Sowers; C Hayes; D Jamadar; D Capul; L Lachance; M Jannausch; G Welch
Journal:  Osteoarthritis Cartilage       Date:  2003-06       Impact factor: 6.576

View more
  34 in total

1.  Relationship between global pulse wave velocity and diastolic dysfunction in postmenopausal women.

Authors:  Pasquale Palmiero; Maria Maiello; David D Daly; Annapaola Zito; Marco Matteo Ciccone; Navin C Nanda
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  The evolving role of biomarkers for osteoarthritis.

Authors:  Muneaki Ishijima; Haruka Kaneko; Kazuo Kaneko
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-08       Impact factor: 5.346

3.  The value of cartilage biomarkers in progressive knee osteoarthritis: cross-sectional and 6-year follow-up study in middle-aged subjects.

Authors:  Jaanika Kumm; Ann Tamm; Mare Lintrop; Agu Tamm
Journal:  Rheumatol Int       Date:  2012-07-21       Impact factor: 2.631

4.  Protein modification by deamidation indicates variations in joint extracellular matrix turnover.

Authors:  Jonathan B Catterall; Ming F Hsueh; Thomas V Stabler; Christopher R McCudden; Michael Bolognesi; Robert Zura; Joanne M Jordan; Jordan B Renner; Sheng Feng; Virginia B Kraus
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

5.  The relationship between urinary C-Telopeptide fragments of type II collagen, knee joint load, pain, and physical function in individuals with medial knee osteoarthritis.

Authors:  Luiz Fernando Approbato Selistre; Glaucia Helena Gonçalves; Fernando Augusto Vasilceac; Paula Regina Mendes da Silva Serrão; Theresa Helissa Nakagawa; Marina Petrella; Richard Keith Jones; Stela Márcia Mattiello
Journal:  Braz J Phys Ther       Date:  2020-02-26       Impact factor: 3.377

6.  Urinary CTX-II concentrations are elevated and associated with knee pain and function in subjects with ACL reconstruction.

Authors:  T L Chmielewski; T N Trumble; A-M Joseph; J Shuster; P A Indelicato; M W Moser; F M Cicuttini; C Leeuwenburgh
Journal:  Osteoarthritis Cartilage       Date:  2012-08-02       Impact factor: 6.576

7.  The relationship between longitudinal serum leptin measures and measures of magnetic resonance imaging-assessed knee joint damage in a population of mid-life women.

Authors:  Carrie A Karvonen-Gutierrez; Siobán D Harlow; Jon Jacobson; Peter Mancuso; Yebin Jiang
Journal:  Ann Rheum Dis       Date:  2013-04-10       Impact factor: 19.103

Review 8.  C-Terminal Cross-Linked Telopeptides of Type II Collagen as Biomarker for Radiological Knee Osteoarthritis: A Meta-Analysis.

Authors:  HongBin Cheng; Baoxi Hao; Jingtao Sun; Mingxi Yin
Journal:  Cartilage       Date:  2018-09-15       Impact factor: 4.634

9.  Recent findings on the role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis.

Authors:  Olimpio Galasso; Filippo Familiari; Marco De Gori; Giorgio Gasparini
Journal:  Adv Orthop       Date:  2012-07-26

10.  Which Predicts Quadriceps Muscle Strength in Knee Osteoarthritis: Biological Markers or Clinical Variables?

Authors:  Neslihan Gökçen; Sibel Başaran; İlke Coşkun Benlidayi; Çiğdem Özdemir; Gülşah Seydaoğlu
Journal:  Arch Rheumatol       Date:  2016-12-15       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.